# US 2001/0025034 A1 · Curcumin and curcuminoid inhibition of angiogenesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025034 A1
- Document ID: US20010025034A1
- Status: Published application
- Kind: A1
- Application number: 09/765,491
- Filed: 2001-01-18
- Published: 2001-09-27
- Earliest claimed: 1999-06-30
- Assignees: Emory University
- Inventors: Jack L. Arbiser
- Web page: https://patentgrep.com/patent/US20010025034A1

## CPC

- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/12: Ketones
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/336: having three-membered rings, e.g. oxirane, fumagillin
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/404: Indoles, e.g. pindolol
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for treating diseases or disorders of the skin which are characterized by angiogenesis have been developed using curcumin and curcumin analogs. Based on the results obtained with curcumin, it has been determined that other angiogenesis inhibitors can also be used to treat these skin disorders. It has further been discovered that curcumin acts to inhibit angiogenesis in part by inhibition of basic fibroblast growth factor (bFGF), and thereby provides a means for treating other disorders characterized by elevated levels of bFGF, such as bladder cancer, using curcumin and other analogues which also inhibit bFGF. Representative skin disorders to be treated include the malignant diseases angiosarcoma, hemangioendothelioma, basal cell carcinoma, squamous cell carcinoma, malignant melanoma and Karposi's sarcoma, and the non-malignant diseases or conditions including psoriasis, lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis.

## Claims

### Claim 1

A method for inhibiting disorders characterized by elevated levels of basic fibroblast growth factor comprising administering to the individual having the disorder an effective amount of a curcuminoid to inhibit the basic fibroblast growth factor.

### Claim 2

The method of claim I wherein the curcuminoid is administered topically.

### Claim 3 (depends on 1)

The method of claim 1 wherein the disorder is bladdar or cervical cancer.

### Claim 4

A method for inhibiting skin disorders selected from the group consisting of lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis comprising administering to the individual in need of treatment thereof an angiogenesis inhibitor in an amount effective to inhibit angiogenesis.

### Claim 5 (depends on 4)

The method of claim 4 wherein the angiogenesis inhibitor is applied topically.

### Claim 6 (depends on 5)

The method of claim 5 wherein the angiogenesis inhibitor is selected from the group consisting of collagenase inhibitors, endostatin, angiostatin, fumagillin derivatives like TNP-470, 2,5-diaryltetrahydrofurans, aminophenylphosphonic acid compounds, 3-substituted oxindole derivatives, thalidomides, penicillamine and IL12.

### Claim 7 (depends on 4)

The method of claim 4 wherein the angiogenesis inhibitor is a curcuminoid.

### Claim 8 (depends on 7)

The method of claim 7 wherein the angiogenesis inhibitor is curcumin.

### Claim 9 (depends on 7)

The method of claim 7 wherein the angiogenesis inhibitor is demethoxycurcumin.

### Claim 10

A method to treat a disorder selected from the group consisting of angiosarcoma, hemangioendothelioma, basal cell carcinoma, squamous cell carcinoma, malignant melanoma and Karposi's sarcoma, and psoriasis, comprising administering to the individual in need of treatment an effective amount to inhibit angiogenesis of a curcuminoid.

### Claim 11 (depends on 10)

The method of claim 10 wherein the angiogenesis inhibitor is curcumin.

### Claim 12 (depends on 10)

The method of claim 10 wherein the angiogenesis inhibitor is demethoxycurcumin.

### Claim 13

A pharmaceutical composition comprising a curcumin in combination with a pharmaceutically acceptable carrier for topical administration, wherein the curcumin is present in a dosage effective to treat a condition selected from the group consisting of lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis.

### Claim 14 (depends on 13)

The composition of claim 13 wherein the carrier is an ointment or gel.

### Claim 15 (depends on 14)

The composition of claim 14 as an ointment or hydrogel containing between one-half percent (0.5%) and five percent (5%) of the curcuminoid.

### Claim 16 (depends on 13)

The composition of claim 13 wherein the carrier is a polymer formulation for implantation.
